Analyst Yaron Werber says Human Genome Sciences new lupus drug Benlysta is being used right now but the door is open for better drugs to enter. Benlysta is the first lupus drug in 50 years so specialists are prescribing it, but according to Yaron are not bowled over with its clinical benefits. He says docs will be open to switch as soon as the next drug comes along with a better clinical profile.
Duh! That's true of most drugs. It would be better to know more about what is specifically lacking in clinical performance with Benlysta. In any event, Werber has downgraded sales estimates and the consequent HGS expected stock price. Investors seem to be paying no attention though. See Fierce Biotech story.
Posted by Bruce Lehr Aug 30th 2011.
Comments